S&P falls for fourth day as Mueller subpoena weighs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Bullish Options Activity in Alibaba (BABA) Targets Upside in Shares -Susquehanna
March 15, 2018 2:41 PM EDTSusquehanna options strategist Alison Edwards notes bullish options activity in Alibaba (NYSE: BABA), investors purchased ~7,500 May 210 Calls for $7.30 and 2,500 Jul 210/250 call spreads for up to $9.00.
... MoreDollar General (DG) PT Raised to $97 at Loop Capital
March 15, 2018 12:50 PM EDTLoop Capital raised its price target on Dollar General (NYSE: DG) to $97.00 (from $87.00) while maintaining a Hold rating.
Analyst Anthony Chukumba notes the company posted solid F4Q 2017 results and they believe the company's much better-than-expected F2018 earnings guidance "is largely a function of the fact... More
RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results
March 15, 2018 9:41 AM EDTRBC Capital analsyt Kennen MacKay was positive on Alexion Pharma (NASDAQ: ALXN) after ALXN-1210 hit its hurdle in the 1st of 2 Phase 3 trials.
MacKay called the results a "win, but note a full re-rate scenario." He sees a 10-15% move.
... MoreDollar General (DG) PT Raised to $125 at Deutsche Bank on 4Q Print; 'Clearing All Major Hurdles'
March 15, 2018 9:10 AM EDTDeutsche Bank raised its price target on Dollar General (NYSE: DG) to $125.00 (from $121.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.
Analyst Paul Trussell comments, "Post DLTRs shortfall, investors were nervous leading into DGs print on... More
JPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results
March 15, 2018 9:06 AM EDTJPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results from the PNH naïve phase 3 study of ALXN1210 versus Soliris.
Analyst Anupam Rama believes that the data is "a clear win for ALXN1210 in... More
Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMO
March 15, 2018 8:57 AM EDTBMO Capital analyst M. Ian Somaiya expects shares of Alexion Pharmaceuticals (NASDAQ: ALXN) trade higher as investors breathe a sigh of relief following release of Phase 3 ALXN-1210 data.
"The treatment naïve study met most investor expectations, meeting the non-inferiority primary endpoint (some... More
